FIGURE 3.
Differentiated expression of NAT2 specimens and its correlation with clinicopathologic characteristics in CRC patients. (A) Differentiated expression of NAT2 in colorectal normal and tumor specimens from TCGA. (B) Paired differentiation analysis for the expression of NAT2 in 44 matched normal and tumor samples derived from the TCGA-CRC expression profile. (C–E) The correlation between NAT2 expression and pathological staging characteristics. (F,G) Differentiated expression of NAT2 in 64 CRC samples and paired adjacent tissues obtained from our hospital (Nanfang Hospital) (F) and the correlation between NAT2 expression and AJCC stage (G). (H) NAT2 mRNA expression in normal and CRC cell lines. (I,J) Survival analysis of CRC patients with different NAT2 expression levels from GSE17538, GSE17536, GSE38832, and GSE12945. [Student’s t test for (A–C,E–G); One-way ANOVA for (D); log-rank test for (I). *, p < 0.05].